293 related articles for article (PubMed ID: 35818856)
1. The role of systemic therapy in melanoma brain metastases: a narrative review.
Saleem K; Davar D
Chin Clin Oncol; 2022 Jun; 11(3):24. PubMed ID: 35818856
[TBL] [Abstract][Full Text] [Related]
2. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases.
Dohm AE; Nakashima JY; Kalagotla H; Jiang SX; Tang JD; Bhandari M; Kim Y; Graham JA; Khushalani NI; Forsyth PA; Etame AB; Liu JK; Tran ND; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Ahmed KA
Eur J Cancer; 2023 Oct; 192():113287. PubMed ID: 37657227
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
Ahmed KA; Abuodeh YA; Echevarria MI; Arrington JA; Stallworth DG; Hogue C; Naghavi AO; Kim S; Kim Y; Patel BG; Sarangkasiri S; Johnstone PA; Sahebjam S; Khushalani NI; Forsyth PA; Harrison LB; Yu M; Etame AB; Caudell JJ
Ann Oncol; 2016 Dec; 27(12):2288-2294. PubMed ID: 27637745
[TBL] [Abstract][Full Text] [Related]
5. Recommended first-line management of brain metastases from melanoma: A multicenter survey of clinical practice.
Jablonska PA; Fong CH; Kruser T; Weiss J; Liu ZA; Takami H; Narita Y; Ynoe de Moraes F; Dasgupta A; Ong CK; Yang JCH; Lee JH; Pavlakis N; Kongkham P; Butler M; Shultz DB
Radiother Oncol; 2022 Mar; 168():89-94. PubMed ID: 35121033
[TBL] [Abstract][Full Text] [Related]
6. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
Lau PKH; Feran B; Smith L; Lasocki A; Molania R; Smith K; Weppler A; Angel C; Kee D; Bhave P; Lee B; Young RJ; Iravani A; Yeang HA; Vergara IA; Kok D; Drummond K; Neeson PJ; Sheppard KE; Papenfuss T; Solomon BJ; Sandhu S; McArthur GA
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625515
[TBL] [Abstract][Full Text] [Related]
7. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
Sloot S; Chen YA; Zhao X; Weber JL; Benedict JJ; Mulé JJ; Smalley KS; Weber JS; Zager JS; Forsyth PA; Sondak VK; Gibney GT
Cancer; 2018 Jan; 124(2):297-305. PubMed ID: 29023643
[TBL] [Abstract][Full Text] [Related]
8. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
[TBL] [Abstract][Full Text] [Related]
9. Melanoma brain metastases: Biological basis and novel therapeutic strategies.
Phadke M; Ozgun A; Eroglu Z; Smalley KSM
Exp Dermatol; 2022 Jan; 31(1):31-42. PubMed ID: 33455008
[TBL] [Abstract][Full Text] [Related]
10. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Meier F; Garzarolli M; Weichenthal M; Kähler K; Grimmelmann I; Gutzmer R; Utikal J; Terheyden P; Herbst R; Haferkamp S; Pfoehler C; Forschner A; Leiter U; Ziller F; Meiss F; Ulrich J; Kreuter A; Gebhardt C; Welzel J; Schilling B; Kaatz M; Scharfetter-Kochanek K; Dippel E; Nashan D; Sachse M; Weishaupt C; Löffler H; Gambichler T; Loquai C; Heinzerling L; Grabbe S; Debus D; Schley G; Hassel JC; Weyandt G; Trommer M; Lodde G; Placke JM; Zimmer L; Livingstone E; Becker JC; Horn S; Schadendorf D; Ugurel S
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028819
[TBL] [Abstract][Full Text] [Related]
11. Melanoma brain metastases - Interdisciplinary management recommendations 2020.
Gutzmer R; Vordermark D; Hassel JC; Krex D; Wendl C; Schadendorf D; Sickmann T; Rieken S; Pukrop T; Höller C; Eigentler TK; Meier F
Cancer Treat Rev; 2020 Sep; 89():102083. PubMed ID: 32736188
[TBL] [Abstract][Full Text] [Related]
12. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
Bander ED; Yuan M; Carnevale JA; Reiner AS; Panageas KS; Postow MA; Tabar V; Moss NS
Cancer; 2021 Jun; 127(12):2062-2073. PubMed ID: 33651913
[TBL] [Abstract][Full Text] [Related]
13. How I treat brain metastases of melanoma.
Eroglu Z; Topcu TO; Yu HM; Margolin KA
ESMO Open; 2022 Dec; 7(6):100598. PubMed ID: 36274439
[TBL] [Abstract][Full Text] [Related]
14. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
Devji T; Levine O; Neupane B; Beyene J; Xie F
JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543
[TBL] [Abstract][Full Text] [Related]
15. BRAF/MEK Inhibition as a Bridge to Immunotherapy for Symptomatic BRAF V600 Melanoma Brain Metastases: A Case Series.
Strelnikov J; Zhou A; Butt O; Ansstas M; Ansstas G
J Natl Compr Canc Netw; 2023 Aug; 21(10):991-999. PubMed ID: 37647938
[TBL] [Abstract][Full Text] [Related]
16. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
[TBL] [Abstract][Full Text] [Related]
17. Advances in the systemic treatment of melanoma brain metastases.
Glitza Oliva IC; Schvartsman G; Tawbi H
Ann Oncol; 2018 Jul; 29(7):1509-1520. PubMed ID: 29790899
[TBL] [Abstract][Full Text] [Related]
18. Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort.
Iorgulescu JB; Harary M; Zogg CK; Ligon KL; Reardon DA; Hodi FS; Aizer AA; Smith TR
Cancer Immunol Res; 2018 Sep; 6(9):1039-1045. PubMed ID: 30002157
[TBL] [Abstract][Full Text] [Related]
19. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
Holbrook K; Lutzky J; Davies MA; Davis JM; Glitza IC; Amaria RN; Diab A; Patel SP; Amin A; Tawbi H
Cancer; 2020 Feb; 126(3):523-530. PubMed ID: 31658370
[TBL] [Abstract][Full Text] [Related]
20. Maximal surgical tumour load reduction in immune-checkpoint inhibitor naïve patients with melanoma brain metastases correlates with prolonged survival.
Voglis S; Schaller V; Müller T; Gönel M; Winklhofer S; Mangana J; Dummer R; Serra C; Weller M; Regli L; Le Rhun E; Neidert MC
Eur J Cancer; 2022 Nov; 175():158-168. PubMed ID: 36126476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]